Company:  SAREPTA THERAPEUTICS, INC ... (SRPT)
Form Type:  DEF 14A
Filing Date:  4/26/2018 
CIK:  0000873303 
Address:  215 FIRST STREET
SUITE 415
 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  617-274-4000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$137.30  
Change: 
0.62 (0.45%)  
Trade Time: 
Jul 17  
Market Cap: 
$9.00B
Trade SRPT now with 

© 2018  
Description of Business
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches for the treatment of rare neuromuscular diseases. Applying our proprietary, highly-differentiated and innovative RNA-targeted platform technologies, we are able to develop candidate therapies for a broad range of diseases and disorders. Our first commercial product in the U.S., EXONDYS 51, was granted accelerated approval by the FDA on September 19, 2016. EXONDYS 51 is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. A summary description of our product and main product candidates is as follows: * EXONDYS 51, our first product, uses our PMO chemistry and exon-skipping technology to skip exon 51 of the dystrophin gene.
Register and access this filing in:     
  FORM DEF 14A
    Proxy Card and Revocation of Proxy
    Stockholder Proposals for the 2019 Annual Meeting
      NAME AND TITLE
      NAME AND TITLE
    ADVISORY VOTE TO APPROVE NAMED EXECUTIVE OFFICER COMPENSATION
      COMPENSATION TABLE
    STOCK OWNED BY SAREPTA THERAPEUTICS, INC. MANAGEMENT AND ...
      BENEFICIAL OWNERS
    AUDIT COMMITTEE REPORT
    Compensation Committee Report
    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
    Compensation Committee Interlocks and Insider Participation
    ANNUAL REPORT
    OTHER MATTERS